Sequoia Capital Israel

Sequoia Capital Israel is a venture capital firm that backs startups and growth companies across seed to late-stage rounds, with a focus on Israel. It invests across sectors including fintech, financial services, internet, mobile, technology, and healthcare, spanning banking, payments, advertising, ecommerce, data, security, software, and related enabling tech. Typical commitments range from 100,000 to 1 million in seed, 1 to 10 million in early venture, and 10 to 100 million in growth rounds. The firm is based in Tel Aviv and operates as part of Sequoia Capital's global network.

Sakshi Chopra

Principal

Fu Xin

Partner

Pushpak Kedia

Shmil Levy

Investor

Ishaan Mittal

Principal

Javier Ng

Yoav Shaked

Investor

Pavel Vyhnalek

Past deals in Washington

Zuper

Series A in 2022
Zuper, Inc. is an information technology company based in Sammamish, Washington, founded in 2016. It specializes in developing a comprehensive field service management platform that enhances collaboration and efficiency for field and remote workforces. The platform provides a suite of tools including work order management, intelligent scheduling, timesheet management, live location tracking, and estimation software. Zuper's solution is designed to integrate seamlessly with various applications and customer relationship management systems, allowing organizations in industries such as cleaning, electrical, plumbing, internet services, and landscaping to optimize their operations. By modernizing field operations, Zuper helps service businesses expand rapidly while improving customer experiences through robust reporting and analytics.

dMed

Series C in 2021
dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.

Outreach

Series G in 2021
Outreach is a sales engagement platform that helps organizations manage and optimize interactions across email, voice, and social channels throughout the customer lifecycle. The platform uses machine learning to guide sales representatives to take the right actions, automate repetitive tasks, and personalize communications while tracking sales activity and performance. It supports account-based, outbound, and inbound sales, as well as sequence and task management, email and activity tracking, and insights that analyze buyer sentiment to optimize content and sequences in real time. By integrating automated alerts, collaboration features, and performance analytics, Outreach aims to increase the volume of qualified meetings and improve the efficiency and effectiveness of customer-facing teams.

dMed

Series C in 2020
dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.